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survival at 1 year was 63%.  Conclusion:  In most patients, 
first-line support by IABP in end-stage cardiomyopathy is as-
sociated with improvement in organ perfusion and clinical 
stabilisation for at least 24 h allowing time for decision mak-
ing on next therapies.  © 2017 The Author(s)
Published by S. Karger AG, Basel 
 Introduction  
 Mechanical circulatory support may be necessary to 
prevent irreversible end-organ damage in cardiogenic 
shock (CS)  [1, 2] . For more than 40 years, the intra-aortic 
balloon pump (IABP) has been used in CS to improve 
coronary and peripheral perfusion via diastolic balloon 
inflation and to augment left ventricular (LV) perfor-
mance via systolic balloon deflation through a decreased 
afterload  [3, 4] . The IABP is safe and minimally invasive, 
but its effectiveness has been questioned and, according 
to the 2016 European Society of Cardiology guidelines, is 
not routinely recommended for CS support  [2] . IABP did 
not improve short- and long-term survival in the setting 
of CS complicating acute myocardial infarction (AMI), as 
reported in the IABP-SHOCK II trial  [5, 6] . Nowadays, 
advanced mechanical support capable to provide greater 
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 Abstract 
 Objectives: Little is known about circulatory support in car-
diogenic shock (CS) from other causes than the acute coro-
nary syndrome or after cardiotomy. We evaluated the effects 
of first-line intra-aortic balloon pump (IABP) support in this 
subpopulation of CS patients.  Methods: A retrospective 
study was performed in 27 patients with CS from end-stage 
cardiomyopathy supported firstly by IABP in the years 2011–
2016.  Results: At 24 h, lactate decreased from 3.2 (2.1–6.8) to 
1.8 (1.2–2.2) mmol/L ( p < 0.001).  Eighteen patients (67%) de-
fined as IABP responders were successfully bridged to either 
recovery ( n = 7), left ventricular assist device ( n = 5), or heart 
transplantation ( n = 6). IABP failed in 9 patients (non-re-
sponders, 33%) who either died ( n = 7) or needed support by 
extracorporeal membrane oxygenation ( n = 2). At 24 h of 
IABP support, urinary output was higher (2,660 [1,835–4,440] 
vs. 1,200 [649–2,385] mL;  p = 0.02) and fluid balance more 
negative (–1,564 [–2,673 to –1,086] vs. –500 [–930 to +240] 
mL;  p < 0.001) in responders than non-responders. Overall 
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output is available, either as percutaneous ventricular as-
sist device (pVAD) or as extracorporeal membrane oxy-
genation (ECMO)  [2] . However, these systems are more 
invasive and not available outside tertiary care centres. 
Although the most frequent cause of CS is acute coronary 
syndrome, non-ischaemic aetiology accounts for up to 
one-fifth of CS cases  [7] . The haemodynamic needs may 
be different in non-ischaemic CS, where low output may 
be triggered by volume overload, versus AMI, where 
myocardial contractile reserve is acutely impaired. There-
fore, in non-ischaemic CS, we aimed to investigate the 
effect of first-line support by IABP on haemodynamic 
stabilisation and selection in subsequent therapies. 
 Patients and Methods 
 Study Population 
 We reviewed the data of all patients supported by IABP at the 
Erasmus Medical Centre (MC), Rotterdam, the Netherlands, be-
tween March 2011 and November 2016. Patients were included in 
the analysis when the indication for IABP was inotropy-dependent 
heart failure with signs of hypoperfusion and tissue hypoxia (e.g., 
blood lactate levels >2 mmol/L, urinary output <30 mL/h during at 
least 4 h, cold extremities, and altered mental state). Criteria for ex-
clusion were: (1) AMI in the previous 30 days; (2) cardiac surgery in 
the previous 30 days; (3) ECMO as first mechanical circulatory sup-
port; and (4) IABP inserted as support for high-risk coronary inter-
vention or cardiac surgery. Among 411 patients supported by IABP 
in the Erasmus MC, there were 27 patients (7%) in whom IABP was 
inserted for refractory heart failure deteriorating following CS not 
caused by acute coronary syndrome or cardiac surgery ( Fig. 1 ). 
 Ethics 
 This retrospective study was conducted according to the pri-
vacy policy of the Erasmus MC and according to the Erasmus MC 
regulations for the appropriate use of data in patient-oriented re-
search.
 IABP Support 
 A Maquet/Datascope fibre-optic IAB (Hilversum, The Neth-
erlands) was inserted by catheterisation of the right or left com-
mon femoral artery using the Seldinger technique either at bed-
side or under fluoroscopic guidance. After insertion, unfraction-
ated heparin was administered intravenously according to our 
institution protocol, aiming to achieve an activated partial 
thromboplastin time between 60 and 80 s. The indication for 
continuation of IABP treatment, weaning, or escalation to other 
mechanical circulatory support was evaluated daily by a multi-
disciplinary team involving an intensive care specialist, a heart 
failure cardiologist, and a cardiothoracic surgeon. In all patients, 
candidacy for an LV assist device (LVAD) or heart transplanta-
tion was evaluated. For the patients already listed for heart trans-
plantation, urgency was requested when IABP support became 
necessary in patients not suitable for LVAD. We defined the suc-
cess of IABP support as haemodynamic improvement allowing 
titration of heart failure medication and weaning from IABP or 
haemodynamic stabilisation until LVAD or heart transplanta-
tion (IABP responders). Failure of IABP support was defined as 
death during support, escalation of temporary mechanical sup-
port to ECMO, or IABP removal due persistent multi-organ fail-
ure and contraindications for LVAD or transplantation (IABP 
non-responders).
 Data Collection  
 Data were retrieved from patient medical records and the local 
hospital database. Standard demographic data and medication 
were recorded at baseline. Patients meeting criteria for LV failure 
(LV ejection fraction <35%) and right ventricular (RV) failure (tri-
cuspid annular plane systolic excursion <1.6 cm, or qualitatively 
assessed moderate or severe RV systolic dysfunction together with 
at least moderate tricuspid regurgitation, and dilated inferior caval 
vein) were classified as biventricular heart failure. The clinical and 
laboratory parameters were collected at baseline and 24 and 48 h 
after IABP insertion from the local electronic hospital database. 
Systemic blood pressure was measured invasively with a radial ar-
terial line. Patients were classified according to the profiles defined 
by the Interagency Registry for Mechanically Assisted Circulatory 
Support (INTERMACS), i.e., class 1 for life-threatening critical CS 
necessitating vasopressor support or class 2 for progressive decline 
in inotropic support  [8] . In addition, the HeartMate II risk score, 
which included age, albumin, and creatinine levels, INR, and cen-
tre volume, was calculated  [8, 9] . Systemic vascular resistance was 
calculated as 80 × (mean arterial pressure – right atrial pressure)/
cardiac output. Pulmonary artery pulsatility index was calculated 
as (systolic pulmonary artery pressure – diastolic pulmonary ar-
tery pressure)/right atrial pressure. RV stroke work index was cal-
culated as stroke volume index × (mean pulmonary artery pressure 
– right atrial pressure) × 0.0136. Estimated glomerular filtration 
rate was calculated from creatinine values using the Cockcroft-
Gault equation. Cumulative 24-h fluid balance was calculated as 
the difference between fluid intake and urinary output. Echocar-
diographic parameters were obtained from the local database. LV 
ejection fraction was estimated based on wall motion index. The 
degree of mitral regurgitation had been graded as absent, mild, 
moderate, or severe according to established echocardiography 
criteria. IABP-related bleeding, infectious and ischaemic compli-
cations, as well as the number of blood transfusions were regis-
tered. 
Study population (7%)
AMI (75%)
High-risk PCI (1%)
High-risk surgery (11%)
Weaning from bypass (4%)
Others (4%)
 Fig. 1. Distribution of indications for intra-aortic balloon pump in 
our Centre. AMI, acute myocardial infarction; PCI, percutaneous 
coronary intervention. 
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 Table 1.  Baseline characteristics of the study population 
Total (N = 27) IABP responders (n = 18) IABP non-responders (n = 9) p value
Demographic data
Age, years 50 (46 – 59) 50 (44 – 59) 51 (47 – 61) ns
Male gender 16 (59) 8 (44) 8 (90) 0.04
Body mass index 24.2 (21.5 – 25.4) 24.9 (21.5 – 26.0) 24.1 (21.7 – 24.6) ns
Cardiomyopathy (non-ischaemic etiology) 21 (78) 15 (83) 6 (67) ns
New-onset heart failure 5 (19) 4 (22) 1 (11) ns
Biventricular failure 16 (59) 11 (61) 5 (56) ns
INTERMACS profile 1 24 (89) 16 (89) 8 (89) ns
HeartMate II risk score 4.8 (3.4 – 8.3) 5.3 (3.7 – 12.4) 4.8 (3.2 – 5.9) ns
Haemodynamic parameters and treatment
Systolic blood pressure, mm Hg 90 (80 – 92) 90 (80 – 94) 89 (81 – 95) ns
Diastolic blood pressure, mm Hg 55 (49 – 60) 56 (47 – 60) 50 (50 – 61) ns
Mean arterial pressure, mm Hg 67 (60 – 71) 66 (59 – 74) 68 (59 – 71) ns
Heart rate, b.p.m. 90 (80 – 107) 95 (80 – 106) 89 (80 – 117) ns
Cardiac indexa, L/min/m2 2.0 (1.6 – 2.1) 1.9 (1.6 – 2.1) 2.0 (1.6 – 2.2) ns
Right atrial pressure, mm Hg 20 (17 – 21) 20 (15 – 20) 20 (19 – 27) ns
Mean pulmonary artery pressurea, mm Hg 31 (23 – 38) 28 (23 – 36) 35 (25 – 39) ns
Pulmonary capillary wedge pressurea, mm Hg 22 (14 – 25) 23 (14 – 26) 21 (15 – 24) ns
Systemic vascular resistancea, dyn × s/cm5 972 (694 – 1,113) 972 (663 – 1,101) 986 (736 – 1,196) ns
Pulmonary artery pulsatility indexa 1.2 (0.5 – 1.4) 0.8 (0.4 – 1.2) 1.4 (1.2 – 1.5) ns
Right ventricular stroke work indexa 3.6 (1.1 – 5.1) 2.8 (0.8 – 4.6) 4.4 (2.1 – 6.5) ns
Right atrial pressure/wedge pressure ratioa 0.9 (0.7 – 1.4) 0.8 (0.7 – 1.9) 1.0 (0.8 – 1.2) ns
Central venous oxygen saturation, % 46 (34 – 61) 54 (45 – 67) 33 (32 – 46) 0.04
Vasopressor (norepinephrine) 19 (70) 13 (72) 6 (67) ns
Inotropes (dobutamine or enoximone) 22 (82) 14 (78) 8 (89) ns
Norepinephrine, μg/kg/min 0.2 (0.1 – 0.3) 0.2 (0.1 – 0.3) 0.2 (0.1 – 0.3) ns
Dobutamine, μg/kg/min 5 (3 – 7) 4 (2 – 7) 6 (3 – 7) ns
Enoximone, μg/kg/min 1 (1 – 2) 1 (1 – 1) 1 (0.5 – 1) ns
Renal replacement therapy before IABP 2 (7) 1 (6) 1 (11) ns
Mechanical ventilation before IABP 6 (22) 4 (22) 2 (22) ns
Biochemistry
Lactate, mmol/L 3.3 (2.1 – 6.8) 3.6 (2.1 – 8.1) 3.2 (2.3 – 5.5) ns
Haemoglobin, mmol/L 7.3 (6.2 – 8.6) 7.6 (6.4 – 8.6) 6.5 (5.9 – 7.5) ns
Bilirubin, μmol/L 34 (21 – 52) 23 (18 – 37) 45 (34 – 102) 0.03
Urea, mmol/L 20 (11 – 30) 18 (10 – 27) 30 (20 – 42) 0.02
Creatinine, μmol/L 201 (124 – 296) 199 (137 – 245) 246 (95 – 355) ns
eGFR, mL/min/1,73 m2 34 (26 – 60) 33 (27 – 49) 34 (21 – 87) ns
C-reactive protein, mg/L 32 (16 – 92) 25 (9 – 54) 55 (33 – 152) 0.01
Sodium, mmol/L 133 (128 – 138) 133 (127 – 135) 134 (129 – 140) ns
Potassium, mmol/L 4.5 (4.1 – 5.0) 4.4 (4.0 – 5.1) 4.7 (4.6 – 5.2) ns
NT-proBNP, pmol/L 1,422 (766 – 3,219) 2,069 (875 – 4,123) 1,094 (255 – 1,856) ns
Glutamic oxaloacetic transaminase, U/L 64 (32 – 336) 123 (35 – 926) 45 (30 – 282) ns
Glutamic pyruvic transaminase, U/L 81 (24 – 369) 119 (24 – 840) 78 (22 – 253) ns
Echocardiography
Left ventricular ejection fraction, % 20 (15 – 25) 22 (19 – 26) 15 (15 – 20) 0.03
Left ventricular end-diastolic diameter, mm 63 (56 – 71) 62 (56 – 68) 63 (55 – 75) ns
E/E´ ratio 18 (13 – 26) 17 (12 – 27) 20 (11 – 30) ns
Mitral regurgitation (moderate or severe) 17 (63) 12 (67) 5 (56) ns
TAPSE, cm 1.3 (1.3 – 1.5) 1.3 (1.2 – 1.5) 1.5 (1.3 – 2.0) ns
Tricuspid regurgitation (moderate or severe) 9 (33) 5 (28) 4 (44) ns
Diameter of the inferior cava, cm 2.4 (2.2 – 2.6) 2.4 (2 – 2.5) 2.4 (2.3 – 2.9) ns
 Ranges and percentages are given in parentheses. INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; 
NT-proBNP, N-terminal pro-B-type natriuretic peptide; eGFR, estimated glomerular filtration rate; IABP, intra-aortic balloon pump; 
TAPSE, tricuspid annular plane systolic excursion. a Data were available for 12/27 (44%) patients.
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 Statistics 
 Continuous variables are reported as medians and interquartile 
ranges (25–75%). Categorical variables are described as counts and 
percentages. Changes among variables at specified times, and dif-
ferences between IABP responders and non-responders were 
compared with Wilcoxon matched-pair signed-rank, Friedman 
2-way ANOVA, or Mann-Whitney U tests (continuous data, when 
appropriate) and the Fisher exact tests (categorical data). Cumula-
tive survival was estimated according to the Kaplan-Meier meth-
od. Statistical significance of all tests was defined as p < 0.05 (two 
sided). Analyses were performed using the Statistical Package for 
Social Sciences (version 23; SPSS, Armonk, NY, USA). 
 Results 
 Baseline Characteristics 
 Baseline characteristics of the 27 patients are presented 
in  Table 1 . All patients were classified as INTERMACS 
class 1 (89%) or 2 (11%), and 59% of the patients had bi-
ventricular failure. All patients were at high risk accord-
ing to the HeartMate II risk score  [8, 9] . Eight (30%) pa-
tients had recurrent ventricular tachycardia.
 Effect of IABP Support  
 Median duration of IABP support was 4 (3–7) days 
and the length of intensive care unit (ICU) stay was 14 
(7–24) days. During IABP support, mean arterial pres-
sure and central venous oxygen saturation increased ( Ta-
ble 2 ). Right atrial pressure decreased and urinary output 
improved, whereas dosages of intravenous furosemide 
could be reduced. Lactate decreased significantly, while 
hyponatremia improved.  Figure 2 illustrates the clinical 
outcome of the patients after IABP support. A total of 18 
patients (67%) had successful IABP treatment and were 
defined as IABP responders. Of them, 7 patients could be 
weaned after 4 (3–4) days of support and continued 
thereafter on medication; 9 patients were supported by 
IABP for 6 (4–9) days until LVAD or heart transplanta-
tion, 1 patient underwent heart transplantation and 1 pa-
tient LVAD implantation after IABP removal at 28 and 
44 days, respectively. IABP failed in 9 patients (33%), de-
fined as non-responders. In this group, 5 patients died 
during IABP support at 3 (2–9) days, 2 died <18 days af-
ter removal of IABP due to other organ failure and con-
traindications to LVAD or transplantation (1 patient had 
persistent estimated glomerular filtration rate <30 mL/
min and the other had cardiac AL-amyloidosis second-
ary to multiple myeloma), and in 2 patients treatment 
was escalated towards veno-arterial ECMO after 3 and 7 
days (these 2 patients underwent later heart transplanta-
tion). 
 Comparison of Clinical and Haemodynamic 
Parameters  
 A comparison of the baseline characteristics between 
IABP responders and non-responders is presented in  Ta-
ble  1 . IABP responders were more frequently female. 
 Table 2.  Changes in haemodynamics and markers of organ perfusion after intra-aortic balloon pump (IABP) insertion in the study pa-
tients
Before IABP 24 h after IABP 48 h after IABP p for trend
Mean arterial pressure, mm Hg 67 (60 – 71) 75 (68 – 82)* 74 (63 – 81)* 0.01
Heart rate, b.p.m. 90 (80 – 107) 88 (79 – 99) 85 (75 – 99) ns
Central venous oxygen saturation, % 46 (34 – 61) 62 (51 – 75)* 57 (49 – 64)* 0.001
Right atrial pressure, mm Hg 20 (17 – 21) 15 (12 – 17)* 12 (10 – 18)* <0.001
TAPSE, cm 1.3 (1.3 – 1.5) –   1.4 (1.0 – 1.5) ns
Tricuspid regurgitation (moderate or severe), n 9 (33) – 8 (30) ns
Furosemide dosage, mg/day i.v. 500 (125 – 1,000) 125 (0 – 500)*   60 (0 – 120)* <0.001
Fluid balance, mL/day 500 (0 – 930) –1,100 (–2,331 to –500)* –816 (–1,800 to –387)* <0.001
Cumulative urinary output, mL 720 (480 – 1,200) 2,329 (1,200 – 3,690)* 2,198 (1,666 – 2,810)* <0.001
Lactate, mmol/L 3.3 (2.1 – 6.8)   1.8 (1.2 – 2.2)*   1.5 (1.1 – 2.4)* <0.001
Sodium, mmol/L 133 (128 – 138) 135 (131 – 139)* 137 (134 – 141)* 0.001
Creatinine, μmol/L 201 (124 – 296) 180 (156 – 252) 186 (131 – 252) ns
Glutamic oxaloacetic transaminase, U/L 64 (32 – 336) 105 (33 – 605) 84 (32 – 424) ns
Glutamic pyruvic transaminase, U/L 81 (24 – 369)   93 (21 – 871) 87 (20 – 773) ns
Bilirubin, μmol/L 34 (21 – 52)   24 (13 – 47) 24 (13 – 47) ns
 Ranges and percentages are given in parentheses. TAPSE, tricuspid annular plane systolic excursion. * p < 0.05 vs. before IABP.
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Central venous oxygen saturation and LV ejection frac-
tion were lower in non-responders. Baseline serum levels 
of bilirubin, urea, and C-reactive protein were signifi-
cantly higher in IABP non-responders than responders. 
 The clinical changes after IABP insertion in both 
groups are presented in  Figure 3 . In IABP responders, 
mean arterial pressure was higher at 48 h and CVP was 
lower at 48 h than in non-responders. Urinary output was 
significantly higher at 24 and 48 h in IABP responders 
than in non-responders, paralleled by a more negative 
fluid balance in responders. However, serum creatinine 
and lactate did not significantly differ between both 
groups. The duration of support and the length of ICU 
stay did not differ between responders and non-respond-
ers (5 [3–7] vs. 4 [3–11] days and 14 [8–24] vs. 8 [5–19] 
days, respectively).
 Complications and Survival 
 Thirty-day mortality was 33% and tended to be higher 
in patients with an ischaemic aetiology (3/6: 50%). Cu-
mulative survival at 1 year was 63% ( Fig. 4 ). One patient 
died during IABP support because of a cerebellar haem-
orrhage in the presence of a cavernous haemangioma. 
Four patients (15%) required blood transfusions during 
IABP support. Two patients developed an access-site hae-
matoma. Positive blood cultures (for  Staphylococcus au-
reus ) were present in 1 patient. 
 Discussion  
 In the present study, we show that first-line support by 
IABP in non-ischaemic CS improves organ perfusion and 
stabilizes the patient for at least 24 h, as shown by de-
creased lactate levels in all patients. After 24 h of IABP 
support, the patients with urinary output > 2,000 mL and 
a negative fluid balance were more likely to be responders 
who could recover or could be maintained on IABP sup-
port until LVAD implantation or heart transplantation. 
 IABP versus Other Forms of Mechanical Circulatory 
Support  
 IABP has been used since the 1960s, and for a long 
time it was the only available mechanical device in CS. 
However, IABP has not improved prognosis in CS com-
plicating AMI  [5, 6] . Refractory low-output heart failure 
not caused by the acute coronary syndrome represents a 
subpopulation of CS patients, accounting for less than 
10% of all indications for mechanical circulatory support 
 [7] . Only few reports describe successful use of IABP sup-
Patients supported
by IABP
(n = 27)
Responders (n = 18)
Bridged to LVAD or HTx
(n = 9)
Survival till
discharge (78%)
Weaned from IABP
(n = 9)
LVAD or HTx (n = 2)
Survival till
discharge (100%)
Discharge on medical
treatment (n = 7)
Non-responders (n = 9)
Death (n = 7)
Escalation to ECMO
(n = 2)
 Fig. 2. Flow chart of outcomes. ECMO, extracorporeal membrane oxygenation; HTx, heart transplantation; 
IABP, intra-aortic balloon pump; LVAD, left ventricular assist device.  
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port as bridge to recovery, LVAD, or transplantation in 
small groups of patients with NYHA class IV heart failure 
not related to the acute coronary syndrome deteriorating 
following CS  [10–13] . Although the definitive treatment 
of refractory heart failure is LVAD implantation or heart 
transplantation, these complex therapies are associated 
with increased mortality in INTERMACS class 1 and 2 
patients  [14, 15] . On the other hand, it has been shown 
that the prognosis of patients with severe hypoperfusion 
bridged to heart transplantation by IABP was similar to 
that of electively transplanted patients  [16] . Thus, stabili-
sation of patients with short-term circulatory support de-
vices is necessary. This provides time for the selection of 
suitable candidates and the evaluation of contraindica-
tions for advanced mechanical support and transplanta-
tion. The level of support is higher by pVAD and ECMO 
than IABP, but a meta-analysis comparing pVAD with 
IABP found no difference in 30-day survival in CS pa-
tients  [17] . The presence of concomitant RV failure has 
been associated with early escalation to advanced me-
chanical circulatory support in patients supported by 
IABP  [18] . The advantages of IABP compared to pVAD 
or ECMO consist in a large availability, a reduced com-
plexity of professional training, the possibility of a rapid 
insertion in the ICU without the need for fluoroscopy, 
and a low complication rate  [10, 19] .
 In our population, IABP support was the last treat-
ment option in 7 patients, who died during support or 
had major contraindications to heart transplantation or 
LVAD. Escalation to ECMO was chosen by a multidisci-
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plinary team for 2 patients after 3 and 7 days of IABP sup-
port, respectively. These patients underwent later heart 
transplantation. IABP support remained necessary and 
provided haemodynamic stability until LVAD implanta-
tion or heart transplantation in 9 of our patients, in agree-
ment with other reports  [12–14] . However, 9 patients 
could be weaned from IABP, of which 7 could be dis-
charged on optimal medication and were alive at the 
1-year follow-up. In a previous report, we described our 
strategy of weaning from mechanic and inotropic sup-
port in low-output heart failure patients and reported a 
high long-term survival in patients able to tolerate 
β-blocker therapy at discharge  [20] .
 Monitoring IABP Response 
 Elevated blood lactate is an important marker of severe 
systemic hypoperfusion leading to abnormal cellular oxy-
gen metabolism  [21] . At 24 h, we found a significant de-
crease in lactate levels in the whole cohort, but lactate was 
not significantly lower in IABP responders than non-re-
sponders. On the other hand, higher levels of C-reactive 
protein and bilirubin baseline values were observed in 
IABP non-responders than IABP responders, showing 
that the success of IABP is less likely to occur in the pres-
ence of inflammation and multi-organ dysfunction; in 
these patients, more advanced mechanical support should 
be considered. Already at 24 h, and persistently at 48 h, the 
improvement in urinary production with a negative fluid 
balance was a useful clinical marker of response to treat-
ment, although serum creatinine levels did not signifi-
cantly improve. This is an interesting clinical observation 
that received less attention in previous reports about IABP 
in non-ischaemic CS. One study on ultrasound spectral 
Doppler estimation of renal flow velocity reported higher 
renal blood flow during IABP support  [22] . Although we 
did not routinely perform haemodynamic measurements 
in the present study, we hypothesize that the decrease in 
LV afterload by IABP increases right to left flow and leads 
to decreased right-sided congestion and increased renal 
perfusion, which result in enhanced diuresis. 
 Survival 
 Our study in patients with end-stage non-ischaemic 
heart failure shows a 1-year survival rate of 63%, which 
was identical to survival rates stated for patients receiving 
IABP for CS from AMI. This finding is in line with an-
other retrospective IABP-CS study  [10] , but in contrast to 
the TandemHeart-CS study by Kar et al.  [23] , who re-
ported a better survival in patients with non-ischaemic 
cardiomyopathy. However, patients categorized as hav-
ing “non-ischaemic CS” presenting with AMI in the 30 
days before study start were excluded in our study, but in 
fact 6 patients (22%) had an ischaemic aetiology and 
tended to have a worse outcome; therefore, these 6 pa-
tients would have been grouped into the ischaemic car-
diomyopathy group in the study by Kar et al.  [23] . 
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 Fig. 4. Kaplan-Meier survival curve of the 
study population versus patients on intra-
aortic balloon pump for shock from acute 
myocardial infarction (AMI) and predict-
ed survival according to the HeartMate II 
risk score. 
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 Limitations 
 The retrospective single-centre design and the small 
sample size, together with the uncontrolled nature of this 
study, are important limitations. Haemodynamic inva-
sive measurements were available for 12 of the 27 pa-
tients. The decisions to wean from IABP support or to 
escalate to ECMO were based on clinical assessment by a 
multidisciplinary team and not on predefined criteria. A 
multivariate analysis of predictors of IABP response 
could not be performed due to the small size of the cohort, 
and instead the differences between groups were tested 
with non-parametric tests. 
 Conclusion 
 This study shows a preserved utility of IABP as first-
line mechanical circulatory support in the subpopulation 
of patients with CS not caused by acute coronary syn-
drome and provides practical guidance for the manage-
ment of these patients. We show that simple clinical pa-
rameters, such as mean arterial pressure, central venous 
pressure, diuresis, and fluid balance can be used to assess 
response and make decisions about further treatment in 
the first 24–48 h of IABP support. The low complexity 
level of IABP management and the low rate of complica-
tions enforce the role of IABP as initial circulatory sup-
port before resource-intensive devices are employed in 
non-ischaemic CS. 
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